Post-approval studies (Phase 4)Study completedNCT02503293
What this trial is testing
Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
Who this might be right for
Primary Immunodeficiency
Octapharma 30